▲ Peaking
Business
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
Obesity Drug
5 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial
A novel injectable drug called CBL-514 is drawing attention for reducing visceral fat and targeting fat cells without Ozempic or surgery.
◼ Archived
Business
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.